We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
The latest trading session saw Pfizer (PFE - Free Report) ending at $28.58, denoting a -0.21% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.46%. Elsewhere, the Dow gained 0.48%, while the tech-heavy Nasdaq added 0.7%.
The drugmaker's stock has dropped by 1.17% in the past month, falling short of the Medical sector's gain of 4.8% and the S&P 500's gain of 4.85%.
The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.16, reflecting a 114.04% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.58 billion, down 39.98% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.54 per share and revenue of $58.83 billion, indicating changes of -76.6% and -41.37%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1% decrease. Pfizer is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 18.56. This signifies a premium in comparison to the average Forward P/E of 15.47 for its industry.
Also, we should mention that PFE has a PEG ratio of 1.86. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.13 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 54, this industry ranks in the top 22% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
The latest trading session saw Pfizer (PFE - Free Report) ending at $28.58, denoting a -0.21% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.46%. Elsewhere, the Dow gained 0.48%, while the tech-heavy Nasdaq added 0.7%.
The drugmaker's stock has dropped by 1.17% in the past month, falling short of the Medical sector's gain of 4.8% and the S&P 500's gain of 4.85%.
The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.16, reflecting a 114.04% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.58 billion, down 39.98% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.54 per share and revenue of $58.83 billion, indicating changes of -76.6% and -41.37%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1% decrease. Pfizer is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Pfizer is currently trading at a Forward P/E ratio of 18.56. This signifies a premium in comparison to the average Forward P/E of 15.47 for its industry.
Also, we should mention that PFE has a PEG ratio of 1.86. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.13 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 54, this industry ranks in the top 22% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.